Lupin Limited has informed stock exchanges about a timeline extension for its subsidiary's acquisition of VISUfarma B.V., a Netherlands-based company. The pharmaceutical company communicated this update through a regulatory filing dated February 27, 2026.

Transaction Details

The acquisition involves Nanomi B.V., Lupin's wholly owned subsidiary in the Netherlands, acquiring the entire share capital of VISUfarma B.V. The company had previously communicated about this transaction through intimations dated September 29, 2025 and December 30, 2025.

Timeline Extension and Pending Approvals

The transaction, which was originally expected to be completed by February 28, 2026, is now anticipated to be completed in April 2026. The extension is attributed to the pending satisfaction of specific closing conditions that are required for the transaction completion. The deal delay reflects the complex nature of cross-border acquisitions where regulatory approvals and other conditions precedent need to be satisfied before transaction closure.

Regulatory Compliance

The update was communicated to both the National Stock Exchange of India Limited and BSE Limited under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The intimation was signed by Amit Kumar Gupta, Company Secretary & Compliance Officer of Lupin Limited.

The company stated that the proposed transaction is still ongoing and emphasized that the completion remains subject to fulfillment of specified closing conditions. This represents a standard approach in cross-border acquisitions where regulatory approvals and other conditions precedent need to be satisfied before transaction closure.

Lupin has received a satisfactory establishment inspection report from the US Food and Drug Administration (FDA) for its Goa manufacturing facility, with voluntary action indicated. The pharmaceutical company announced this regulatory milestone through an official disclosure, with the inspection conducted from November 10 to November 21, 2025.

FDA Inspection Details

The US FDA's establishment inspection of Lupin's Goa facility concluded with a satisfactory rating and Voluntary Action Indicated (VAI) classification. The company made the announcement through a regulatory filing under Regulation 30 of SEBI listing requirements.

Management Response

Nilesh Gupta, Managing Director of Lupin, expressed satisfaction with the inspection outcome. "We are pleased to have received the EIR with a VAI classification from the US FDA for our Goa facility. This outcome reflects our continued focus on quality excellence and regulatory compliance, reinforcing our commitment to delivering safe and effective medicines to patients worldwide," Gupta stated.

Regulatory Significance

Receiving a satisfactory inspection report from the US FDA is crucial for pharmaceutical manufacturers seeking to maintain market access in the United States. The satisfactory rating demonstrates that Lupin's Goa facility complies with current Good Manufacturing Practices (cGMP) and other FDA requirements.

The voluntary action indicated (VAI) classification typically means that while some observations may have been noted during the inspection, they do not warrant immediate regulatory action. This outcome allows the facility to continue its manufacturing operations without disruption.

Manufacturing Operations Impact

This positive FDA inspection outcome supports Lupin's ability to continue supplying pharmaceutical products to the US market from its Goa manufacturing facility. The satisfactory rating reinforces the company's commitment to maintaining high-quality manufacturing standards across its global operations and ensures continued regulatory compliance for its US market activities.